Suppressive effect of the tablet containing Salacia chinensis extract on postprandial blood glucose

Japanese Pharmacology and Therapeutics

Volumn 38, Issue 6, 2010, Pages 545-550

  Kobayashi, Masakazu ^a   Akaki, Junji ^a   Yamashita, Kousaku ^a   Morikawa, Toshio ^b   Ninomiya, Kiyofumi ^b   Muraoka, Osamu ^b   Yoshikawa, Masayuki ^c  

^a Kobayashi Pharmaceutical Co   (Japan)

^b KINKI UNIVERSITY   (Japan)

^c KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Neokotalanol; Postprandial blood glucose; Salaria chinensis; Tablet

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; INSULIN; PLACEBO; PLANT EXTRACT; SALACIA CHINENSIS EXTRACT; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SALACIA; SALACIA CHINENSIS;

EID: 77954650723     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, et al. Acarbose for prevention of type 2 diabetes mellitus : the STOP-NIDDM randomised trial. Lancet 2002 ; 359 (9323) : 2072-7. (Pubitemid 34680970)
2. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K, et al. Voglibose for prevention of type 2 diabetes mellitus : a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009 ; 373 (9675) : 1607-14.
3. 1c. Diabetes Care 2003 ; 26 (3) : 881-5.
4. 1c levels. Diabetes Res Clin Pract 2007 ; 77 (2) : 280-5.
5. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999 ; 22 (6) : 920-4.
6. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance : the STOP-NIDDM trial. JAMA 2003 ; 290 (4) : 486-94. (Pubitemid 37430502)
7. Muraoka O, Morikawa T, Miyake S, Akaki J, Ninomiya K, Yoshikawa M. Quantitative analysis of neosalasinol and neokotalanol, another potent α -glucosidase inhibitors from Salacia species, by ion pair-LC and MS.